ReviewRegenerative biomaterials2025
Smart materials strategy for vascular challenges targeting in-stent restenosis: a critical review.
Review in Regenerative biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Hematologic complications and design challenges in cardiovascular devices.Communications engineering · 2026Review
- An Overview of Advanced Materials and Manufacturing Strategies for 3D-Printed Bioengineered Vascular Stents: Toward Next-Generation Drug Delivery Applications.Pharmaceutics · 2026Review
- Microvascular Failure in the Aging Brain: Converging Pathways of Oxidative Stress, Inflammation, and Endothelial Decline.Biomedicines · 2026Review
- Emerging Technologies for Exploring the Cellular Mechanisms in Vascular Diseases.International journal of molecular sciences · 2025Review
- Smart PH-responsive drug-eluting balloons: a next-generation strategy for in-stent restenosis.Annals of medicine and surgery (2012) · 2025Article
- Integrated Polymeric Sensors in Heart and Blood Vessel Monitoring: A Review.Sensors (Basel, Switzerland) · 2025Review
- Emerging 4D Fabrication of Tubular Structures and Clinical Challenges: Critical Perspective.ACS materials Au · 2025Review
- Next-generation biodegradable cardiovascular stents: integrating biosensors and personalized drug delivery for improved outcomes.Annals of medicine and surgery (2012) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In-stent restenosis (ISR) presents a major challenge in vascular disease management, often leading to complications and repeated interventions. This review article explores the potential of existing smart materials strategies in addressing ISR, emphasizing advancements in materials science and biomedical engineering. We focus on innovative solutions such as bioactive coatings and responsive polymers that offer targeted responses to ISR-related internal and external triggers. These smart materials can dynamically adapt to the physiological conditions within blood vessels, responding in real time to various stimuli such as pH, oxidative stress and temperature. Moreover, we discuss preclinical progress and translational challenges associated with these materials as they move toward clinical applications. The review highlights the importance of controlled drug release and the need for materials that can degrade appropriately to minimize adverse effects. This work aims to identify critical research gaps and provide guidance to encourage interdisciplinary efforts to advance the development of smart stent technologies. Ultimately, the goal is to improve patient outcomes in vascular interventions by leveraging the capabilities of intelligent biomaterials to enhance ISR management and ensure better long-term efficacy and safety in-stent applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.